William Waddill

Will Waddill began his career 30 years ago in commercial banking and public accounting and has been in the biotechnology industry for over 25 years. Currently he sits on the boards of Protagonist Therapeutics and Arrowhead Pharmaceuticals. Most recently he was Senior Vice President, CFO of Calithera Bioscience where he completed over $106 million in equity financing including the company’s $80 million IPO in October 2014. Prior to Calithera, Mr. Waddill was Senior Vice President, CFO, at OncoMed Pharmaceuticals from 2007 to 2014, where he was responsible for all corporate financial matters, most notably their $94 million Initial Public Offering in 2013, private equity financings of $126 million, and three collaborations valued at $6.1 billion. Prior to OncoMed, Will was Senior Vice President, CFO, at Ilypsa, where he was the finance lead for the companies $420 million acquisition by Amgen. Before joining Ilypsa, he was the founder and principal at Square One Finance, a life science consulting business managing the finances of 33 start-up biotechnology companies including eight that became public and six that have been acquired. In addition to being on the boards of Protagonist and Arrowhead, Will is an emeritus board member of the Association of Bioscience Financial Officers (ABFO), where he was Chairman in 2016 as well as co-chair of the ABFO 2014 National Conference. Formerly he served as Chairman of the Biotechnology Industry Organization (BIO) BIO Business Solutions Advisory Board as well as the Finance and Tax Committee. Will has testified in Washington D.C. on behalf of the biotech industry in front of the Senate Finance Committee and Congressional Capital Markets Subcommittee. He received a BS in accounting from the University of Illinois, Chicago, and certification as a public accountant (inactive) after working at PriceWaterhouseCoopers and Deloitte in Boston.